DAX ®13.137,70-0,16%TecDAX ®2.994,40-0,36%Dow Jones27.766,29-0,20%NASDAQ 1008.265,62-0,22%
finanztreff.de

PRESS RELEASE: EVOTEC, INTEGRA HOLDINGS AND YISSUM ESTABLISH LAB555 TO FAST TRACK EARLY-STAGE DRUG DEVELOPMENT

| Quelle: Dow Jones Newsw... | Lesedauer etwa 6 min. | Text vorlesen Stop Pause Fortsetzen


DGAP-News: Evotec SE / Key word(s): Miscellaneous
EVOTEC, INTEGRA HOLDINGS AND YISSUM ESTABLISH LAB555 TO FAST TRACK
EARLY-STAGE DRUG DEVELOPMENT

2019-10-23 / 07:30
The issuer is solely responsible for the content of this announcement.

? _FIRST ACADEMIC BRIDGE PARTNERSHIP IN ISRAEL AIMS TO TRANSLATE
EARLY-STAGE RESEARCH FROM THE HEBREW UNIVERSITY ("HU") OF JERUSALEM INTO
INDUSTRIAL DRUG DEVELOPMENT PROJECTS_

? _LAB555 LEVERAGES INTEGRA'S SKILL IN IDENTIFYING AND DEVELOPING
PROMISING EARLY-STAGE THERAPEUTIC PROJECTS, YISSUM'S TRANSLATIONAL
EXPERTISE AND EVOTEC'S INDUSTRIAL DRUG DEVELOPMENT PLATFORM_

*Hamburg, Germany, 23 October 2019:* Evotec SE (Frankfurt Stock Exchange:
EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the inauguration of
LAB555, an academic BRIDGE partnership with Integra Holdings and Yissum, the
Technology Transfer Company of the Hebrew University of Jerusalem. The
partnership aims to expedite drug discovery and development by providing
efficient translation of early stage Hebrew University research.

LAB555 leverages the innovation expertise of Integra Holdings, an investment
company focused on delivering breakthrough research from the Hebrew
University's life sciences, and Yissum, leaders in technology transfer, with
access to Evotec's leading industrial drug development platform. The LAB555
partnership endeavours to accelerate multiple academic research projects to
value inflection points that will allow the creation of company spin-outs
focused on the development of first-in-class therapeutics.

No financial details of the collaboration were disclosed.

*Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: *"We are
delighted to see the further roll-out of our BRIDGE model to Israel. LAB555
is a great addition to our BRIDGE family and we are confident that with our
strong partners, Integra Holdings and Yissum, we will be able to accelerate
the efficient development of next-generation drugs. We hope that ultimately
our efforts will bring benefits to a large number of patients across
different indications, who currently have a significant unmet medical need."

*Dr Liana Patt, Chief Executive Officer of Integra Holdings, said:* "We are
excited to enter this collaboration with Evotec, which underscores the
promise of Evotec's development capabilities and Hebrew University's life
sciences innovation, as well as supporting Integra's vision to identify and
advance HU's promising early stage discovery platforms into drug candidates
for development in Integra's expanded portfolio of companies."

*Dr Yaron Daniely, Chief Executive Officer of Yissum, added:* "The LAB555
partnership highlights Hebrew University's ground breaking and advanced
research in the life sciences and addresses an urgent global need to explore
and initiate accelerated modes of therapeutic drug development."

*About Evotec's BRIDGE model: Partnering to accelerate innovation*
Evotec has created a new paradigm to translate early-stage academic research
to drug discovery and development called "BRIDGE" (Biomedical Research,
Innovation & Development Generation Efficiency), an integrated fund and
award framework to tap into exciting academic science to accelerate the
formation of spin-out companies and generate partnerships with Pharma and
biotech. Through these efforts, Evotec has defined a new formula for
fast-track early-stage drug discovery. Since the launch of the BRIDGE model
in 2016, Evotec has formed and funded six partnerships, termed LAB282,
LAB150, LAB591, LAB031, LAB10x, and LAB555. For more information about
Evotec's BRIDGE initiatives, please go to www.evotec.com/en/innovate/bridges
[1].

_ABOUT INTEGRA HOLDINGS_
_Founded in 2012 by Yissum, the Technology Transfer Company of the Hebrew
University, Integra Holdings' mission is to bring the Hebrew University's
Life Science Academic Excellence to market._
_Integra Holdings is a unique venture organization with a balanced portfolio
of investments, based on an exclusive selection of life science companies,
and focused on proprietary, first-in class innovations in the fields of
biotechnology, pharmaceuticals, diagnostics and medical devices._
_Integra Holdings takes a hands-on approach by providing its portfolio
companies with the strategic planning, business development and research and
development guidance they need to bring their technologies to market._
_For more information, please visit _www.integra-holdings.com [2]_._

_ABOUT YISSUM_
Yissum is the technology transfer company of The Hebrew University of
Jerusalem. Founded in 1964, it serves as a bridge between cutting-edge
academic research and a global community of entrepreneurs, investors, and
industry. Yissum's mission is to benefit society by converting extraordinary
innovations and transformational technologies into commercial solutions that
address our most urgent global challenges. Yissum has registered over 10,000
patents globally; licensed over 900 technologies and has spun out more than
180 companies. Yissum's business partners span the globe and include
companies such as Boston Scientific, Google, ICL, Intel, Johnson & Johnson,
Merck, Microsoft, Novartis and many more. For further information please
visit www.yissum.co.il [3]_._

_ABOUT EVOTEC SE_
_Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide and our more than 2,800
employees provide the highest quality_ stand-alone and integrated drug
discovery and development solutions. We cover all activities from
target-to-clinic to meet the industry's need for innovation and efficiency
in drug discovery and development (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuronal diseases, diabetes and
complications of diabetes, pain and inflammation, oncology, infectious
diseases, respiratory diseases and fibrosis. On this basis, Evotec has built
a broad and deep pipeline of approx. 100 co-owned product opportunities at
clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has
established multiple long-term alliances with partners including Bayer,
Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi,
Takeda, UCB and others. For additional information please go to
www.evotec.com [4] _and follow us on Twitter_ @Evotec [5]_._

FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking statements
are neither promises nor guarantees, but are subject to a variety of risks
and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.

Contact Evotec SE:
Gabriele Hansen, SVP Corporate Communications, Marketing & Investor
Relations, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

2019-10-23 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard);
Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
EQS News ID: 894639

End of News DGAP News Service

894639 2019-10-23


1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=85183a255cbce07ef356ad9db9d34181&application_id=894639&site_id=vwd&application_name=news
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=eff7409d80f71dcdd1840477b21d88a5&application_id=894639&site_id=vwd&application_name=news
3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=2a447adc47cdbbc1cb95d0226b0c7664&application_id=894639&site_id=vwd&application_name=news
4: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=d9f30c4aeb65d3276d5bd878be7dc75c&application_id=894639&site_id=vwd&application_name=news
5: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=174f1f6538cbb01e3ef3386d1481ea5f&application_id=894639&site_id=vwd&application_name=news


(END) Dow Jones Newswires

October 23, 2019 01:30 ET ( 05:30 GMT)
Werbung

Passende Hebelprodukte von

WKN Bezeichnung Hebel
Long  DC04GS EVOTEC SE INH O.N. WaveXXL L 18 (DBK) 7,068
Werbung

Das könnte Sie auch interessieren

News-Suche

Suchbegriff:
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Elon Musk hat vor in der Nähe von Berlin eine Gigafabrik zu bauen. Ist das eher ein Segen für die Region und Deutschland oder eher eine Kampfansage an die deutschen Autobauer?
Jetzt abstimmen!
Alle Umfragen ansehen